Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Attention figureheads..
View:
Post by BlueFranky on Apr 11, 2024 10:48pm

Attention figureheads..

 
As per Knox's post, we're looking at a 4.5 billion dollar global PDT market .. going Beyond 9 billion in the next 8 years
 
Given our current phase 2 stats and projected outcome as well as the war chest of patents including the most recent regarding "liquid cancers", anyone care to speculate on the percentage of the global ptd ww could realistically target?

And based on that percentage, what would be earnings per share and the appropriate PE attached to the share price going forward?

(I think we're taking out long before that has a chance to develop) 

Thanks in advance.
Comment by Galaxym31 on Apr 11, 2024 11:39pm
Ten billion takeout .
Comment by chry200030 on Apr 12, 2024 12:01am
That is actually a pretty good guess. Buy and hold folks... 
Comment by Alamir1111 on Apr 12, 2024 8:51am
Pp at .18 warrants .25.
Comment by riverrrow on Apr 12, 2024 9:14am
Are the warrants 2 years or 5 years?  Thanks.
Comment by Alamir1111 on Apr 12, 2024 9:28am
One guy mentioned he got in at that price don't know more .Suggest call Matthew  P
Comment by Legit62 on Apr 12, 2024 9:42am
is that for upcoming PP ????
Comment by chry200030 on Apr 12, 2024 12:42pm
That's not in 2024. They have some work to do yet. But once the train leaves the station,   it will move fast. 
Comment by Dumbeldorfwhite on Apr 12, 2024 10:25am
18 cent pp, hahahahahah and you guys are talking 10 billion buyout. What a good ole boys club.
Comment by Canucks1717 on Apr 12, 2024 1:57pm
Anything positive too add to this board??
Theralase Technologies Inc.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250